Microchip-based Delivery System Development
Traditional therapeutic approaches often fail to deliver sufficient drug concentrations to the tumor site while minimizing systemic toxicity. Recent advancements in microchip technology offer innovative solutions for targeted drug delivery, enhancing the effectiveness of therapeutic agents against brain tumors. Alfa Cytology specializes in the development and optimization of microchip-based delivery systems tailored for brain tumor therapies.
Introduction to Microchip-Based Delivery Systems for Brain Tumors
Microchip-based delivery systems leverage microfluidic technologies to create devices that can precisely control the release of drugs. These systems are designed to mimic natural physiological conditions, allowing for the sustained release of therapeutics directly at the tumor site. By circumventing the BBB and delivering drugs in a controlled manner, microchips can significantly improve treatment outcomes for patients with brain tumors.
Fig.1 Schematic representation of a droplet generator microchip. (Park J.H., et al., 2024)
Research indicates that microchips can facilitate localized delivery of chemotherapeutics, reducing the required dosage and associated side effects. For instance, studies have demonstrated that using microchip devices can enhance drug penetration into tumor tissues, thereby increasing the efficacy of treatments such as doxorubicin and temozolomide. Furthermore, these devices can be integrated with real-time monitoring technologies, enabling the assessment of therapeutic response and adjustment of drug delivery protocols based on individual patient needs.
Microchip-Based Therapeutic Development for Brain Tumors
Examples of glioblastoma-on-a-chip models for therapeutic applications.
| Therapy |
Targets |
Cell Sources |
Main Materials |
Technologies |
| Chemotherapy |
Temozolomide (TMZ) |
U87-MG, U251-MG |
Polydimethylsiloxane (PDMS) |
Microfluidic chip and soft lithography |
| Chemotherapy |
TMZ |
HUVECs, Patient's primary GBM |
Collagen Hydrogel Precursor |
Three dimensional bioprinting |
| Chemotherapy |
TMZ and BEV |
Patient's primary GBM |
Poly(ethylene) Glycol Diacrylate (PEGDA) Hydrogel |
Microfluidic chip and photolithography |
| Immunotherapy |
Anti-PD-1 Immunotherapy |
Patient's primary GBM, hBMVECs, TAM, CD8+T-cell |
PDMS |
Microfluidic chip and soft lithography |
| Immunotherapy |
CAR-T |
U87-MG Human's primary T cells |
Collagen and Fibronectin |
NR |
Our Services
Alfa Cytology specializes in the development and optimization of microchip-based delivery systems tailored for brain tumor therapies. Our comprehensive services encompass the entire lifecycle of microchip development, from initial concept design to final implementation.
Custom Microchip Design and Fabrication
Our team of experts employs microfabrication techniques to create custom microchips that meet specific therapeutic requirements. Utilizing materials such as PDMS (polydimethylsiloxane) and glass, we can produce devices that offer superior biocompatibility and functionality.
- Microfluidic Drug Delivery Systems Development
- Smart Drug Delivery Systems Development
- Electrokinetic Drug Delivery Systems Development
- Implantable Microchips Systems Development
- Polymer-based Microchip Systems Development
Contact Us
For more information about our microchip-based delivery systems and how they can transform brain tumor treatment, please contact us at Alfa Cytology. Our dedicated team of experts is ready to assist you in advancing your projects and achieving your therapeutic objectives.
Reference
- Staicu, C E, et al. (2021) Lab-on-a-chip platforms as tools for drug screening in neuropathologies associated with blood–brain barrier alterations[J]. Biomolecules. 2021, 11(6): 916.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
